Kornimate/medical-research-clean huggingface dataset:
3d-ct-guided percutaneous radiofrequency thermocoagulation for tumor-related trigeminal neuralgia

Conditions: Trigeminal Neuralgia, Secondary

Summary: this study is designed to investigate the effectiveness and safety of 3d-ct-guided percutaneous radiofrequency thermocoagulation for the treatment of tumor-related trigeminal neuralgia.

approximately 1-13% of trigeminal neuralgia cases are secondary to intracranial tumors, and this condition is referred to as tumor-related trigeminal neuralgia (trtn). trtn can result from a lesion affecting any location along the pathway of the trigeminal nerve, such as meckel's cave, the posterior fossa, and the cerebellopontine angle. the posterior fossa is the most common location of trtn, whereas meningioma and epidermoid cysts are the most common pathologies. the goals of trtn treatment include controlling tumors and relieving pain. tumor resection is regarded as the most effective treatment, and complete tumor removal is often followed by complete pain remission. however, for patients who cannot undergo the risk of a craniotomy and those with end-stage of malignant tumors or slow-growing benign tumors, surgery may not be the best choice. conservatively, medication is considered the first-line therapy for relieving pain. however, pharmacology cannot provide satisfactory relief for all patients, and some patients may experience intolerable side effects. for these patients, minimally invasive interventional techniques are preferred. radiosurgery has been commonly performed for the treatment of trtn with promising efficacy. however, this intervention is associated with delayed latency of response. percutaneous radiofrequency thermocoagulation (prft) is a low-risk, minimally invasive technique with an acute success rate of 97.6-99%. prft remains the most common percutaneous treatment for tn. in addition, this popular procedure may also safely and effectively be repeated if pain recurs. the prft procedure involves positioning the radiofrequency (rf) needle at the gasserian ganglion via the foremen ovale. suboptimal piercing may lead to unpleasant complications, including cerebrospinal fluid leakage, cranial nerve (vi) palsy and intracranial hemorrhage. recently, computed tomography (ct) has been demonstrated to be a useful method to identify the optimal position and predict the intraoperative difficulties of the intervention.

Eligibility criteria:
inclusion criteria: * age\>18 years, * typical tn symptoms in the same lateral as intracranial tumors, * uncontrolled symptoms or intolerable side effects of medication, * pain duration longer than 90 days * brain magnetic resonance imaging (mri)confirmed that the trigeminal pain was secondary to intracranial tumors. exclusion criteria: * patients with infection at the puncture site, * coagulopathy, * epilepsy, * other causes of tn, * a history of mental disorders or anesthetic drug abuse.

Keywords: tumor-related trigeminal neuralgia percutaneous radiofrequency thermocoagulation three-dimensional computed tomography
comparison of the effects of two concentrations of adrenaline (0.33 mg/l vs 1 mg/l) in the irrigation serum of arthroscopic shoulder surgery

Conditions: Shoulder Rotator Cuff Tendinitis

Summary: the addition of adrenaline to the arthroscopic irrigation serum is used during rotator cuff surgery to limit intraoperative bleeding and ensure a clear view. two concentrations of adrenaline are commonly used in practice: 1mg/l or 0.33 mg/l. the aim of this study is to determine which of these two doses provides better clarity of the surgical field with less impact on the patient's cardiovascular parameters.

a prospective, randomised, double-blind, multicentre study in two parallel groups of 85 patients comparing two concentrations of adrenaline in the irrigation fluid of an arthroscopy (0.33 mg/l vs. 1 mg/l): maximum duration of patient participation in the study = 1 day.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age, having read and signed the consent form for participation in the study after a reflection period (approximately 15 minutes) * patient with a rotator cuff pathology (subacromial impingement, long biceps tendinopathy or rotator cuff tendinopathy) * patient for whom an arthroscopic surgical indication has been given exclusion criteria: * allergy to epinephrine * history of takotsubo cardiomyopathy * coagulation disorder * patient under court protection, guardianship or curatorship * patient not affiliated to the french social security system * patient participating in another therapeutic protocol * breastfeeding woman, * pregnant woman or woman of childbearing age without highly effective contraception for the duration of the study (surgically sterile, intrauterine device (\> 14 days), hormonal contraception (same dose and formulation for at least 6 months), sexual abstinence. women of childbearing age, i.e. fertile, are considered to be post-menopausal unless they are permanently infertile or have undergone surgical sterilisation. a post-menopausal condition is defined as the absence of menstruation for 12 months without any other medical cause * patient unable to understand informed information and/or give written informed consent: dementia, psychosis, disturbed consciousness, non-french speaking patient
genetic risk assessment for cancer education and empowerment (grace) project

Conditions: Breast Cancer; Ovarian Cancer

Summary: grace is a randomized 3-arm trial to determine the comparative effectiveness of two remote cancer communication interventions: 1) a targeted generic print (tp) or 2) a tailored telephone-based counseling and navigation intervention (tcn). post-award, the target sample size was revised to (n=642) with nih permission.

there is increasing evidence that activated and engaged patients who are equipped with necessary skills and information are more likely to follow through with recommended care and have better health outcomes at reduced costs. identification of individuals at increased risk of hereditary breast and ovarian cancer (hboc) is crucial for cancer survivors and their families to benefit from biomedical advances in cancer prevention, early detection, treatment and survivorship. the primary purpose of this study is to assess the feasibility and acceptability of two remote interventions aimed at promoting cancer genetic risk assessment (cgra) for hboc. the randomized controlled trial will have 3 arms: usual care (uc) vs. targeted generic print (tp) vs. tailored telephone counseling and navigation intervention (tcn).

Eligibility criteria:
inclusion criteria: breast cancer * hispanic or non-hispanic * female * 21 years of age or older * english-speaking * breast cancer history * breast cancer at the age of 50 or younger or * triple-negative breast cancer or * two or more primary breast cancers ovarian cancer * hispanic or non-hispanic * female * 21 years of age or older * english-speaking * history of ovarian, fallopian, or peritoneal cancer diagnosed at any age exclusion criteria: have had prior genetic counseling or testing for hereditary breast and/or ovarian cancer

Keywords: genetic testing prevention
efficacy and safety of polylevolactic acid injection combined with 1565nm non-ablative fractional laser in the treatment of striae distensae

Conditions: Striae Distensae

Summary: 1. striae distensae (sd), also known as stretch marks, are common, permanent dermal lesions that can be symptomatic and are considered aesthetically undesirable; thus, they pose a significant psychosocial and therapeutic challenge. sd arise in areas of dermal stretching and most commonly occur on the abdomen, breasts, buttocks, and thighs. most literature has described sd during pregnancy(striae gravidarum) and puberty, with reported prevalences varying from 11% to 88%. hormonal influences, reduced genetic expression of fibronectin, collagen, and elastin, and mechanical stretching of the skin have all been postulated to contribute to sd formation. in the acute phase, sd appear as red/violaceous lesions (striae rubrae; sr) that can be raised and symptomatic. the chronic form (striae albae; sa) exists as hypopigmented dermal depressions. 2. polylevolactic acid(plla) is at present one of the most promising biodegradable polymers (biopolymers) and has been the subject of abundant literature over the last decade. plla can be processed with a large number of techniques and is commercially available (large-scale production) in a wide range of grades. 3. previous studies have found that 1565-nm laser can promote the synthesis of types i, iii, and vii collagen and elastin, as well as the remodeling of dermal collagen. according to previous studies, dermal collagen deposition and remodeling may be related to the mechanism by which 1565-nm laser improves sd.


Eligibility criteria:
inclusion criteria: 1. age: 18-50 years old, regardless of gender; 2. the clinical diagnosis was atrophic stria; 3. patients with normal blood routine, liver and kidney function, and preoperative infection; 4. able to communicate well with researchers and comply with the overall test requirements; 5. willing to take and retain photos before and after treatment; 6. volunteer and sign an informed consent form. exclusion criteria: 1. scar constitution; 2. acute or chronic skin infections (including bacteria, viruses, and fungi) exist near the treatment area; 3. those who are allergic to any component of the product; 4. those who have been injected with anticoagulant drugs; 5. those who have used other drugs, other substances, and other implant agents; 6. patients with severe primary and psychiatric disorders such as heart, brain, liver, kidney, hematopoietic system, endocrine system, etc; 7. history of peripheral vascular disease, long-term alcoholism, diabetes, immunosuppression, disorder, drug abuse, etc; 8. pregnant and lactating women; 9. those who are critically ill and difficult to accurately evaluate the effectiveness and safety of the product.

Keywords: polylevolactic acid striae distensae 1565nm non-ablative fractional laser treatment
assessment of skin tolerance and efficacy of a cosmetic product after 5 days of use on subjects with atopic dermatitis

Conditions: Atopic Diathesis; Eczema-prone Skin

Summary: the aim of this study is to compare the efficacy and tolerability and of a cosmetic product to one that is already available on the market (benchmark product). efficacy is assessed by instrumental measurements of skin condition, clinical examinations, and questionnaires.

the objective of this exploratory study is to investigate the efficacy and tolerability of a cosmetic product on subjects with atopic dermatitis after 5 days of use in comparison to a benchmark product. the efficacy will be evaluated via instrumental measurements of skin hydration by corneometer, transepidermal water loss by tewameter and erythema by chromameter as well as by evaluation of itch by using a numerical rating scale (nrs). for efficacy and tolerability evaluation an objective and, in the case of adults, an additional subjective dermatological assessment will be performed.

Eligibility criteria:
inclusion criteria: * written informed consent of the subject to participate in the study, or, for underaged subjects of the parents/ legal guardians to let their child participate in the study * willingness to actively participate in the study and to come to the scheduled visits or, for underaged subjects, willingness of the parents/ legal guardians to actively support their child's participation in the study and to come to the scheduled visits with their child * female and/or male * children from 6 months to 14 years of age and adult subjects between 18 and 65 years of age * eczema-prone skin and atopic diathesis, diagnosed by the dermatologist exclusion criteria: * female subjects: pregnancy or lactation * drug addicts, alcoholics * aids, hiv-positive or infectious hepatitis * conditions which exclude a participation or might influence the test reaction/evaluation * participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area * cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years * insulin-dependent diabetes mellitus * one of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension, cardiovascular diseases * documented allergies to cosmetic products and/ or ingredients, skin care and/or skin cleansing products * wounds, moles, tattoos, scars, excessive hair growth, etc. at the test area that could influence the investigation * systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study * systemic therapy with anti-phlogistic agents or analgetics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study
pd-1 knockout engineered t cells for muscle-invasive bladder cancer

Conditions: Invasive Bladder Cancer Stage IV

Summary: this study will evaluate the safety of pd-1 knockout engineered t cells in treating metastatic advanced bladder cancer. blood samples will also be collected for research purposes.

this is a dose-escalation study of ex-vivo knocked-out, expanded, and selected pd-1 knockout-t cells from autologous origin. patients are assigned to 1 of 3 treatment groups to determine the maximal tolerant dose. after the lower number of cycles are considered tolerant, an arm of the next higher number of cycles will be open to next patients. biomarkers and immunological markers are collected and analyzed as well.

Eligibility criteria:
inclusion criteria: * pathologically verified stage iv muscle-invasive bladder cancer with measurable lesions (on ct: longest diameter of tumoral lesion \>=10 mm, shorted diameter of lymph node \>=15 mm; measurable lesions should not have been irradiated) * progressed after all standard treatment * performance score: 0-1 * expected life span: \>= 6 months * toxicities from prior treatment has resolved. washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy * major organs function normally * women at pregnant ages should be under contraception * willing and able to provide informed consent exclusion criteria: * pathology is mixed type * emergent treatment of tumor emergency is needed * poor vasculature * coagulopathy, or ongoing thrombolytics and/or anticoagulation * blood-borne infectious disease, e.g. hepatitis b * history of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician * with other immune diseases, or chronic use of immunosuppressants or steroids * compliance cannot be expected * other conditions requiring exclusion deemed by physician
extended spectrum betalactamase producing bacteria; epidemiology and treatment in non-hospitalized patients

Conditions: Urinary Tract Infection; Infection Due to ESBL Bacteria; Environmental Contamination of ESBL

Summary: this project aims at investigating the duration of human fecal carriage of bacteria harboring plasmid-borne resistance genes expressing extended spectrum beta-lactamases (esbl), risk factors for infections with such bacteria and persistence, mobility and spread of esbl in the environment and within households. it also aims to compare different methods of detecting esbl carriage and treat patients with urinary tract infection caused by these bacteria.


Eligibility criteria:
inclusion criteria: * patients \>=18 of age with a urine culture yielding e. coli or k. pneumoniae \>10.000 colony forming units/ml. exclusion criteria: * patients who have lived in norway for \<1 year * patients who are unable to answer a questionaire * patients who have been infected with an esbl producing bacteria before * patients who have been admitted to a hospital or a long term care facility for \>24 hours during the past 31 days.

Keywords: urinary tract infection esbl treatment carriage risk factors water contamination
virtual reality job interview training in severe mental illness

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Depressive Disorder

Summary: this is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (vr-jit). northwestern university is partnering with thresholds inc. to evaluate the effectiveness of vr-jit at improving interviewing skills and access to employment. in addition, we will evaluate the cost effectiveness of vr-jit and the process for implementing vr-jit at thresholds.


Eligibility criteria:
inclusion criteria: 1. over the age of 18 2. diagnosis of any of the following: 1. any chronic schizophrenia spectrum disorder, including schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder, other specified schizophrenia spectrum and related disorder, and unspecified schizophrenia spectrum and related disorders; 2. any bipolar spectrum disorder beyond bipolar type i and ii to include cyclothymia, other specified bipolar and related disorder, and unspecified bipolar and related disorders; 3. any depressive disorder, including disruptive mood dysregulation disorder, major depressive disorder, persistent depressive disorder, other specified depressive disorder, and unspecified depressive disorder; 4. posttraumatic stress disorder 3. fluency in english 4. 6th grade reading level 5. enrolled in supported employment/individual placement support (ips) 6. active ips enrollee as indicated by at least 1 contact with his/her employment specialist in the past 30 days. 7. currently unemployed or underemployed 8. planning to go on interviews within 4 weeks of registration on study. 9. willing to be video recorded for certain study elements. 10. must have given signed, informed consent prior to registration on study. exclusion criteria: 1. documented developmental or learning disability. 2. medical condition that may compromise cognition (e.g., parkinson's disease, alzheimer's disease, huntington's chorea, moderate or greater tbi). 3. uncorrected vision or hearing problems 4. active suicidal ideation within the last 30 days with at least some intent to act, with or without a specific plan; this would be reflected in a score of 4 or 5 on the suicidal ideation section of the columbia suicide severity rating scale (cssrs) 5. a past suicide attempt within the past 30 days that did not include preparatory acts or behavior, but was defined by a potentially self-injurious act committed with at least some wish to die as a result of the act.
monitoring pregnant women for antimalarial drug resistance

Conditions: Malaria

Summary: annually, malaria affects an estimated 229 million people, causing 409,000 deaths (who 2019) mostly in africa. despite a substantial decline in malaria-related maternal and child deaths in recent years, progress in controlling malaria has been slower than anticipated and uneven across countries. covid-19-related disruption of malaria control activities will likely further slow the pace and lead to an even greater burden in the near future. one of the greatest challenges delaying progress in malaria elimination is antimalarial drug resistance. recent reports of the emergence of artemisinin-resistant parasites in parts of africa are the cause of even greater concern, since the loss of frontline treatment efficacy could bring about a dramatic reversal of progress. large-scale genetic surveillance of plasmodium is an effective tool for rapid detection of changes in drug efficacy, enabling countries to switch to effective preventive and curative treatments when necessary. the implementation of genetic surveillance has proven very successful in small, low malaria burden countries. however, in large, high malaria burden countries such implementation is operationally and economically more complex. screening pregnant women attending antenatal care (anc) services can be a practical and economical strategy for estimating malariometric parameters, with fewer limitations and challenges than conventional survey methodologies in children. the present study aims to demonstrate that this is also true for the genetic surveillance of antimalarial drug resistance.


Eligibility criteria:
inclusion criteria: * pregnancy or for children age \<14 years old and in primary school exclusion criteria: * refusal to participate (i.e., consent is not given by the participant for women or by the parents in the case of children)

Keywords: antimalarial drug resistance
omission of axillary surgery in breast cancer patients

Conditions: Breast Cancer; Sentinel Lymph Node; Breast Neoplasms

Summary: the treatment and prognosis of breast cancer (bc) are dependent on its molecular subtype and nodal burden. in early bcs with favourable molecular subtype, the incidence of axillary node involvement is low. however, these patients are still subjected to an axillary operation, which can result in additional cost, operating time and morbidities. similarly, in patients with limited nodal burden of 1-2 metastatic nodes, there is emerging evidence that these patients may need sentinel lymph node biopsy (slnb) only, instead of an axillary clearance (ac), which has more surgical morbidities. we aimed to determine if axillary surgery could be safely tailored in bc patients based on their molecular subtype and nodal burden, without compromising their oncological outcomes. this could in turn reduce the morbidities associated with the axillary surgery, total 350 patients will be enrolled. 50 patients with early bc and favourable molecular subtype will be enrolled in a pilot study a (sentiomit), whereby slnb is omitted. for eligible patients who declined study a and other stage i-ii patients, with preoperative n0 status, undergoing upfront surgery but did not meet the inclusion criteria of study a, these patients will be enrolled into study b (sentimacro) to undergo slnb. in study b, the patients will be categorized based on slnb into 3 groups with 100 patients in each arm: b1 with pn0, b2- 1-2 metastatic nodes and b3- \>/=3 metastatic nodes. in study b, we aim to investigate if the b2 group (100 patients) can be treated with a less invasive procedure of slnb alone instead of ac, without affecting oncological outcomes. b1 and b3 are controls. the outcomes for study a and b include short term outcomes such as morbidity rates, cost and operating time savings. long term outcomes include recurrence and survival rates. this study will allow individualisation of axillary surgery based on the patient's molecular subtype and nodal burden, to benefit patients' care.


Eligibility criteria:
inclusion criteria: * female patients aged \>/=55 years old * unifocal cancer on imaging * breast tumour size based on imaging of \</=3cm * no evidence of axillary adenopathy on imaging * patients with strongly positive er and pr and negative her2 on biopsy * grade 1-2 tumour on core biopsy * patient who opt for mastectomy exclusion criteria: * patients with t3/t4 or stage iv disease, patients with preoperative known n+ disease, bilateral breast cancers, patients planned for neoadjuvant chemotherapy, patients with other malignancies.